CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental…

Posted: December 10, 2021 at 1:55 am

TryptageniX will research and develop new sustainable methods of manufacturing therapeutic compounds commercially with increased reproducibility and reliability for clinical use. This partnership will also leverage CB Therapeutics’ versatile platform to propel the development of new chemical entities for next-generation mental health treatments. TryptageniX will research and develop new sustainable methods of manufacturing therapeutic compounds commercially with increased reproducibility and reliability for clinical use. This partnership will also leverage CB Therapeutics’ versatile platform to propel the development of new chemical entities for next-generation mental health treatments

Read the original here:
CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental...

Related Posts